Susanna Edith Medellín-Garibay

Susanna Edith Medellín-Garibay

Auto-generated profile, based on publicly available information

Susanna Edith Medellín-Garibay

Facultad de Ciencias Químicas, Universidad Autónoma de San Luis Potosí

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 November 2015 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
SMSusanna E. Medellín-Garibay
Susanna E. Medellín-Garibay
BOBelén Ortiz-Martín
Belén Ortiz-Martín
ARAída Rueda-Naharro
Aída Rueda-Naharro
BGBenito García
Benito García
SRSilvia Romano-Moreno
Silvia Romano-Moreno
EBEmilia Barcia
Emilia Barcia
The objectives of this study were to characterize the population pharmacokinetics of vancomycin in trauma patients and to propose dosing schemes to optimize therapy. Trauma patients from Hospital Universitario Severo Ochoa (Spain) receiving intravenous vancomycin and routine therapeutic drug monitoring were included. Concentrations and time data were retrospectively collected, and population modelling was performed with NONMEM 7.2; internal and external validations were performed to probe the final model. Finally, several simulations were executed to propose dosing guidelines to reach expected vancomycin concentrations. A total of 118 trauma patients were included; the population was 45% males, with a mean age of 77 years (range 37–100 years) and a mean total body weight (TBW) of 72 kg (range 38–110 kg). The pharmacokinetics of vancomycin was best described by a two-compartment open model; creatinine clearance (CLCR) was related to vancomycin clearance (0.49 ± 0.04 L/h), being diminished by the presence of furosemide (0.34 ± 0.05 L/h). TBW influenced both the central volume of distribution (V1 = 0.74 ± 0.1 L/kg) and peripheral volume of distribution (V2 = 5.9 ± 2 L/kg), but patients with age >65 years showed a larger V1 (1.07 ± 0.1 L/kg). Bootstrapping was performed to internally validate the stability of the final model. External validation was developed using an alternate population of 40 patients with the same characteristics. The validated model was compared with population pharmacokinetic models previously published and showed better predictive performance for trauma patients than the current one. This final model allowed us to propose a new practical dose guideline to reach higher trough concentrations (15–20 mg/L) and AUC0–24/MIC ratios of more than 400 after 4 days of vancomycin treatment. A new population model was described for trauma patients to optimize vancomycin therapy, showing precise predictive performance to be applied for therapeutic drug monitoring and providing a new practical dose guideline that considers CLCR and concomitant administration of furosemide for these patients.

19 August 2019 in Biomedical Chromatography
Verified
Journal Article
Closed access
PDF file
MRMaribel Rodríguez‐Aguilar
Maribel Rodríguez‐Aguilar
SRSofía Ramírez‐García
Sofía Ramírez‐García
CICésar A. Arturo Ilizaliturri-Hernández
César A. Arturo Ilizaliturri-Hernández
AGAlejandro Gómez‐Gómez
Alejandro Gómez‐Gómez
EVEvelyn Van‐Brussel
Evelyn Van‐Brussel
ROGELIO FLORES RAMIREZROGELIO FLORES RAMIREZ
ROGELIO FLORES RAMIREZ

1 December 2017 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
SMSusanna Edith Medellín-Garibay
Susanna Edith Medellín-Garibay
SRSilvia Romano-Moreno
Silvia Romano-Moreno
PTPilar Tejedor-Prado
Pilar Tejedor-Prado
NRNoelia Rubio-Álvaro
Noelia Rubio-Álvaro
ARAida Rueda-Naharro
Aida Rueda-Naharro
EBEmilia Barcia
Emilia Barcia
Pathophysiological changes involved in drug disposition in critically ill patients should be considered in order to optimize the dosing of vancomycin administered by continuous infusion, and certain strategies must be applied to reach therapeutic targets on the first day of treatment. The aim of this study was to develop a population pharmacokinetic model of vancomycin to determine clinical covariates, including mechanical ventilation, that influence the wide variability of this antimicrobial. Plasma vancomycin concentrations from 54 critically ill patients were analyzed simultaneously by a population pharmacokinetic approach. A nomogram for dosing recommendations was developed and was internally evaluated through stochastic simulations. The plasma vancomycin concentration-versus-time data were best described by a one-compartment open model with exponential interindividual variability associated with vancomycin clearance and the volume of distribution. Residual error followed a homoscedastic trend. Creatinine clearance and body weight significantly dropped the objective function value, showing their influence on vancomycin clearance and the volume of distribution, respectively. Characterization based on the presence of mechanical ventilation demonstrated a 20% decrease in vancomycin clearance. External validation (n= 18) was performed to evaluate the predictive ability of the model; median bias and precision values were 0.7 mg/liter (95% confidence interval [CI], −0.4, 1.7) and 5.9 mg/liter (95% CI, 5.4, 6.4), respectively. A population pharmacokinetic model was developed for the administration of vancomycin by continuous infusion to critically ill patients, demonstrating the influence of creatinine clearance and mechanical ventilation on vancomycin clearance, as well as the implications for targeting dosing rates to reach the therapeutic range (20 to 30 mg/liter).

1 February 2017 in Science of The Total Environment
Verified
Journal Article
Closed access
ROGELIO FLORES RAMIREZROGELIO FLORES RAMIREZ
ROGELIO FLORES RAMIREZ
FPFj Pérez-Vázquez
Fj Pérez-Vázquez
MRM Rodríguez-Aguilar
M Rodríguez-Aguilar
SMSe Medellín-Garibay
Se Medellín-Garibay
EBE Van Brussel
E Van Brussel
FDF Díaz-Barriga
F Díaz-Barriga

31 October 2019 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
SMSusanna E. Medellin-Garibay
Susanna E. Medellin-Garibay
NHNadia Hernández-Villa
Nadia Hernández-Villa
LCLourdes Cecilia Correa-González
Lourdes Cecilia Correa-González
MMMiriam Nayeli Morales-Barragán
Miriam Nayeli Morales-Barragán
KVKarla Paulina Valero-Rivera
Karla Paulina Valero-Rivera
SRSilvia Romano-Moreno
Silvia Romano-Moreno

1 December 2015 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
PDF file
SMS. E. Medellín-Garibay
S. E. Medellín-Garibay
NCN. Cortez-Espinosa
N. Cortez-Espinosa
RMR. C. Milán-Segovia
R. C. Milán-Segovia
MMM. Magaña-Aquino
M. Magaña-Aquino
JVJ. M. Vargas-Morales
J. M. Vargas-Morales
SRS. Romano-Moreno
S. Romano-Moreno
Tuberculosis (TB) remains a major public health issue due to the increasing incidence of type 2 diabetes mellitus (T2DM), which exacerbates the clinical course of TB and increases the risk of poor long-term outcomes. The aim of this study was to characterize the pharmacokinetics of rifampin (RIF) and its relationship with biochemical and immunological parameters in patients with TB and T2DM. The biochemical and immunological parameters were assessed on the same day that the pharmacokinetic evaluation of RIF was performed. Factors related to the metabolic syndrome that is characteristic of T2DM patients were not detected in the TB-T2DM group (where predominant malnutrition was present) or in the TB group. Percentages of CD8 + T lymphocytes and NK cells were diminished in the TB and TB-T2DM patients, who had high tumor necrosis factor alpha (TNF-α) and low interleukin-17 (IL-17) levels compared to healthy volunteers. Delayed RIF absorption was observed in the TB and TB-T2DM patients; absorption was poor and slower in the latter group due to poor glycemic control. RIF clearance was also slower in the diabetic patients, thereby prolonging the mean residence time of RIF. There was a significant association between glycemic control, increased TNF-α serum concentrations, and RIF pharmacokinetics in the TB-T2DM patients. These altered metabolic and immune conditions may be factors to be considered in anti-TB therapy management when TB and T2DM are concurrently present.